Monte Rosa Therapeutics (GLUE) Operating Income (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Operating Income of -$50.0 million for Q1 2026, down 213.62% year-over-year from $44.0 million in Q1 2025, and down 0.64% quarter-over-quarter from -$49.7 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Operating Income (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- In Q1 2026, Operating Income fell 213.62% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$148.3 million (down 6864.68% YoY), while the FY2025 annual figure was -$54.2 million, up 33.17% from the prior year.
- Operating Income for Q1 2026 stood at -$50.0 million, down from -$49.7 million in the prior quarter.
- The five-year high for Operating Income was $44.0 million in Q1 2025, with the low at -$50.0 million in Q1 2026.
- The 5-year median for Operating Income is -$32.6 million (2024), against an average of -$25.9 million.
- Peak annual rise in Operating Income reached 226.01% in 2025, while the deepest fall reached 482.31% in 2025.
- Monte Rosa Therapeutics' Operating Income stood at -$32.5 million in 2022, then retreated by 7.31% to -$34.9 million in 2023, then jumped by 137.3% to $13.0 million in 2024, then plunged by 482.31% to -$49.7 million in 2025, then retreated by 0.64% to -$50.0 million in 2026.
- Business Quant data shows GLUE's Operating Income at -$50.0 million in Q1 2026, -$49.7 million in Q4 2025, and -$33.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | -49.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.13 Mn |
| Mar 31, 2026 | -50.03 Mn |
| Dec 31, 2025 | -49.72 Mn |
| Sep 30, 2025 | -32.98 Mn |
| Jun 30, 2025 | -15.55 Mn |
| Mar 31, 2025 | 44.04 Mn |
| Dec 31, 2024 | 13.00 Mn |
| Sep 30, 2024 | -26.53 Mn |
| Jun 30, 2024 | -32.64 Mn |
| Mar 31, 2024 | -34.95 Mn |
| Dec 31, 2023 | -34.86 Mn |
| Sep 30, 2023 | -36.97 Mn |
| Jun 30, 2023 | -37.22 Mn |
| Mar 31, 2023 | -34.26 Mn |
| Dec 31, 2022 | -32.49 Mn |
| Sep 30, 2022 | -28.36 Mn |
| Jun 30, 2022 | -27.23 Mn |
| Mar 31, 2022 | -24.30 Mn |
| Dec 31, 2021 | -23.39 Mn |
| Sep 30, 2021 | -19.87 Mn |